The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
Open accessAbstract
Data on the long-term effects of interferon alfa (IFN) treatment on disease progression and mortality in patients with chronic hepatitis B (CHB) are limited. To evaluate factors that influence clinical outcome and survival, we performed a follow-up study on 165 hepatitis B e antigen (HBeAg) positive CHB patients treated with IFN between 1978 and 2002. The median IFN dose was 30 megaunits (MU)/week (range, 2-70 MU/week), and the median duration of therapy was 16 weeks (range, 1-92 weeks). Response to treatment was defined as HBeAg loss within 12 months after the end of IFN therapy. Median follow-up was 8.8 years (range, 0.3-24 years). Fifty-four patients (33%) responded to IFN treatment. Relapse (HBeAg reactivation) occurred in 7 of the 54 (13%) responders. Fifty-two percent of the responders lost hepatitis B surface antigen (HBsAg) as compared with 9% of the nonresponders (P < .001). Liver histology showed a decreased necroinflammatory activity and less progression of fibrosis in responders. Twenty-six patients died during follow-up. Hepatocellular carcinoma (HCC) was found in 8 patients, 6 of whom were nonresponders. Of the two responders who developed HCC, one patient had relapsed after discontinuation of therapy. Multivariate analysis showed significantly improved survival (relative risk (RR) of death 0.28, 95% CI 0.10-0.78) and reduced risk of developing HCC (RR 0.084, 95% CI 0.09-0.75) in responders. In conclusion, response to IFN therapy results in a prolonged clinical remission with an increased rate of HBsAg seroconversion and improved liver histology. Our results indicate that after correction for baseline factors, response to IFN therapy increases survival and reduces the risk of developing HCC. (Hepatology 2004;39:804-810.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Wong, D. K. H., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 984
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 840
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Lin, S.-M., Sheen, I.-S., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (1999) · Hepatology · doi:10.1002/hep.510290312 · Cited by 444
Realdi, G., The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP), Fattovich, G., Hadziyannis, S., Schalm, S. W., Almasio, P., Sanchez-Tapias, J., Christensen, E., Giustina, G., & Noventa, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80115-0 · Cited by 301
Self-citationMcMahon, B. J. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.5.1051 · Cited by 273
Yuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L. (2001) · Hepatology · doi:10.1053/jhep.2001.25273 · Cited by 232
Fattovich, G., Giustina, G., Realdi, G., Corrocher, R., & Schalm, S. W. (1997) · Hepatology · doi:10.1002/hep.510260536 · Cited by 229
Self-citation
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Liaw, Y.-F., & Chu, C.-M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60207-5 · Cited by 1,218
Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Self-citationOmata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Dienstag, J. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801644 · Cited by 961
Chronic Hepatitis B Infection: A Review
Tang, L. S. Y., Covert, E., Wilson, E., & Kottilil, S. (2018) · JAMA · doi:10.1001/jama.2018.3795 · Cited by 657
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Buster, E. H. C. J., Hansen, B. E., Lau, G. K. K., Piratvisuth, T., Zeuzem, S., Steyerberg, E. W., & Janssen, H. L. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.061 · Cited by 393
Self-citationBuster, E. H. C. J., Flink, H. J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., So, T. M. K., Feinman, S. V., Mach, T., Akarca, U. S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.031 · Cited by 393
Self-citationEntecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
Gish, R. G., Lok, A. S., Chang, T., de Man, R. A., Gadano, A., Sollano, J., Han, K., Chao, Y., Lee, S., Harris, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.025 · Cited by 367
Self-citationChan, H. L., Wong, V. W., Tse, A. M., Tse, C., Chim, A. M., Chan, H., Wong, G. L., & Sung, J. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.09.005 · Cited by 350
Treatment predictors of a sustained virologic response in hepatitis B and C
Kau, A., Vermehren, J., & Sarrazin, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.013 · Cited by 324
Marcellin, P., Bonino, F., Lau, G. K. K., Farci, P., Yurdaydin, C., Piratvisuth, T., Jin, R., Gurel, S., Lu, Z.-M., Wu, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.006 · Cited by 315
Sonneveld, M. J., Rijckborst, V., Boucher, C. A. B., Hansen, B. E., & Janssen, H. L. A. (2010) · Hepatology · doi:10.1002/hep.23844 · Cited by 292
Self-citationCirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma
Yang, J. D., Kim, W. R., Coelho, R., Mettler, T. A., Benson, J. T., Sanderson, S. O., Therneau, T. M., Kim, B., & Roberts, L. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.08.019 · Cited by 266
Flink, H. J., van Zonneveld, M., Hansen, B. E., de Man, R. A., Schalm, S. W., Janssen, H. L. A., & for the HBV 99-01 Study Group* (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00418.x · Cited by 262
Self-citationGish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
Keeffe, E. B., Zeuzem, S., Koff, R. S., Dieterich, D. T., Esteban–Mur, R., Gane, E. J., Jacobson, I. M., Lim, S. G., Naoumov, N., Marcellin, P., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.004 · Cited by 257
Metadata
- Authors
- van Zonneveld, M., Honkoop, P., Hansen, B. E., Niesters, H. G. M., Murad, S. D., de Man, R. A., Schalm, S. W., & Janssen, H. L. A.
- Venue
- Hepatology
- Published
- 2004-03
- Volume
- 39
- Issue
- 3
- Pages
- 804-810
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1964039671
- Cited by
- 322
- References
- 14
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.